Loading company…
Pear Bio develops microtumor technology for testing cancer treatments.
Pear Bio combines organ-on-chip technology, 3D cell culture and computer vision to model tumors and assess drug effects. The technology is intended for cancer research and testing. Founded in 2017, the company is based in Canterbury, UK. It raised USD 14 million in Series A funding in May 2023.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in